Zurück zur Übersicht
| Biotechnology journal. 2022 Jan 25. doi: 10.1002/biot.202100422 |
| Designed SARS-CoV-2 receptor binding domain variants form stable monomers. |
| Klausberger M1, Kienzl NF2, Stadlmayr G3, Grünwald-Gruber C4, Laurent E5, Stadlbauer K6, Stracke F7, Vierlinger K8, Hofner M9, Manhart G10, Gerner W11, Grebien F12, Weinhäusel A13, Mach L14, Wozniak-Knopp G15 |
 Author information
|
|
Abstract The receptor binding domain (RBD) of the SARS-CoV-2 spike (S)-protein is a prime target of virus-neutralizing antibodies present in convalescent sera of COVID-19 patients and thus is considered a key antigen for immunosurveillance studies and vaccine development. Although recombinant expression of RBD has been achieved in several eukaryotic systems, mammalian cells have proven particularly useful. We aimed to optimize RBD produced in HEK293-6E cells towards a stable homogeneous preparation and addressed its O-glycosylation as well as the unpaired cysteine residue 538 in the widely used RBD (319-541) sequence. We found that an intact O-glycosylation site at T323 is highly relevant for the expression and maintenance of RBD as a monomer. Furthermore, we show that deletion or substitution of the unpaired cysteine residue C538 reduces the intrinsic propensity of RBD to form oligomeric aggregates, concomitant with an increased yield of the monomeric form of the protein. Bead-based and enzyme-linked immunosorbent assays utilizing these optimized RBD variants displayed excellent performance with respect to the specific detection of even low levels of SARS-CoV-2 antibodies in convalescent sera. Hence, these RBD variants could be instrumental for the further development of serological SARS-CoV-2 tests and inform the design of RBD-based vaccine candidates. This article is protected by copyright. All rights reserved. |
|
This article is protected by copyright. All rights reserved. |
|
KEYWORDS: COVID-19, antibody assay validation, antigen stability, receptor binding domain, recombinant expression |
|
Publikations ID: 35078277 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
